References
- Peltola H. Meningococcal disease–still with us. Rev Infect Dis 1983; 5: 71–91
- Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369: 2196–210
- van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13: 144–66
- Steven N, Wood M. The clinical spectrum of meningococcal disease, for the age group 15–19 y. Meningococcal disease, KAV Cartwright. Wiley, Chichester 1995; 177–205
- Vogel U, Claus H. Molecular epidemiology of Neisseria meningitidis. Front Biosci 2003; 8: 14–22
- Vienne P, Ducos-Galand M, Guiyoule A, Pires R, Giorgini D, Taha M-K, et al. The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis 2003; 37: 1639–42
- Massari P, Ram S, Macleod H, Wetzler LM. The role of porins in neisserial pathogenesis and immunity. Trends Microbiol 2003; 11: 87–93
- Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. Clin Microbiol Rev 1989; 2(Suppl)118–24
- Domingo P, Muniz-Diaz E, Baraldes MA, Arilla M, Barquet N, Pericas R, et al. Relevance of genetically determined host factors to the prognosis of meningococcal disease. Eur J Clin Microbiol Infect Dis 2004; 23: 634–7
- Emonts M, Hazelzet JA, de Groot R, Hermans PWM. Host genetic determinants of Neisseria meningitidis infections (erratum appears in Lancet Infect Dis 2003;3:815). Lancet Infect Dis 2003; 3: 565–77
- Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Maïnassara HB, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44: 657–63
- Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344: 1378–88
- Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338: 1093–6
- Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23: 2191–6
- Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outer membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281: 1520–7
- van Alphen L. Multivalent meningococcal B OMV vaccines. Serogroup B meningococcal vaccine meeting, Atlanta, GA, USA 2005.
- Zimmer SM, Stephens DS. Serogroup B meningococcal vaccines. Curr Opin Investig Drugs 2006; 7: 733–9
- Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007; 31: 3–14
- Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006; 103: 10834–9
- Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect Immun 2005; 73: 6838–45
- Olcen P, Danielsson D, Kjellander J. The use of protein A-containing staphylococci sensitized with anti-meningococcal antibodies for grouping Neisseria meningitidis and demonstration of meningococcal antigen in cerebrospinal fluid. Acta Pathol Microbiol Scand 1975; 83: 387–96
- Abdillahi H, Poolman JT. Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett 1987; 48: 367–71
- Mölling P, Unemo M, Bäckman A, Olcen P. Genosubtyping by sequencing group A, B and C meningococci: a tool for epidemiological studies of epidemics, clusters and sporadic cases. Apmis 2000; 108: 509–16
- Jacobsson S, Issa M, Unemo M, Bäckman A, Mölling P, Sulaiman N, et al. Molecular characterization of group A Neisseria meningitidis isolated in Sudan 1985–2001. Apmis 2003; 111: 1060–6
- Olcen P, Fredlund H. Do we miss cases of meningococcal meningitis/septicaemia?. Epi aktuellt 2003; 2: 1
- Smith I, Bjornevik AT, Augland IM, Berstad A, Wentzel-Larsen T, Halstensen A. Variations in case fatality and fatality risk factors of meningococcal disease in western Norway, 1985–2002. Epidemiol Infect 2006; 134: 103–10
- Gottfredsson M, Diggle MA, Lawrie DI, Erlensdottir H, Hardardottir H, Kristinsson KG, et al. Neisseria meningitidis sequence type and risk for death, Iceland. Emerg Infect Dis 2006; 12: 1066–73
- Sharip A, Sorvillo F, Redelings MD, Mascola L, Wise M, Nguyen DM. Population-based analysis of meningococcal disease mortality in the United States, 1990–2002. Pediatr Infect Dis J 2006; 25: 191–4
- Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004; 42: 5146–53
- Barr J, Danielsson D. Septic gonococcal dermatitis. Br Med J 1971; 1: 482–5
- Hotopp JC, Grifantini R, Kumar N, Tzeng YL, Fouts D, Frigimelica E, et al. Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology 2006; 152: 3733–49
- Claus H, Vogel U, Swiderek H, Frosch M, Schoen C. Microarray analyses of meningococcal genome composition and gene regulation: a review of the recent literature. FEMS Microbiol Rev 2007; 31: 43–51